Wird geladen...
Acute onset of fingolimod-associated macular edema
PURPOSE: Fingolimod is among the first oral disease-modifying agents for the treatment of relapsing-remitting multiple sclerosis (MS). Despite its favorable safety profile, fingolimod may cause macular edema, a significant adverse event, which occurs within the first 4 months of therapy. Macular ede...
Gespeichert in:
| Veröffentlicht in: | Am J Ophthalmol Case Rep |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Elsevier
2016
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5757484/ https://ncbi.nlm.nih.gov/pubmed/29503930 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajoc.2016.09.005 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|